Keyword Analysis & Research: alogliptin moa

drugbank.com

https://go.drugbank.com/drugs/DB06203

WebAlogliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor used to treat hyperglycemia in patients with type 2 diabetes mellitus.

DA: 10 PA: 52 MOZ Rank: 56

nih.gov

https://www.ncbi.nlm.nih.gov/books/NBK507809/

WebMay 1, 2023 · This activity outlines the indications, mechanism, pharmacology, contraindications, and adverse events associated with alogliptin drug therapy. Alogliptin was first approved by the FDA in …

DA: 97 PA: 10 MOZ Rank: 2

uptodate.com

https://www.uptodate.com/contents/dipeptidyl-peptidase-4-dpp-4-inhibitors-for-the-treatment-of-type-2-diabetes-mellitus

WebApr 27, 2023 · INTRODUCTION. Glucagon-like peptide 1 (GLP-1)-based therapies (eg, dipeptidyl peptidase 4 [DPP-4, DPP4] inhibitors, GLP-1 receptor agonists) affect …

DA: 4 PA: 78 MOZ Rank: 61

microsoft.com

https://go.microsoft.com/fwlink/?linkid=2100071&clcid=0x409

Common brand names: NesinaOVERVIEWSIDE EFFECTSINTERACTIONSDOSAGEInteractionsInteractionsProduct interactions for this drug/drug-class include:Eliglustat with Weak CYP2D6 Inhibitors (Severe Interaction)Tamoxifen with Selected Weak CYP2D6 Inhibitors (Moderate Interaction) Eliglustat with Weak CYP2D6 Inhibitors (Severe Interaction) Tamoxifen with Selected Weak CYP2D6 Inhibitors (Moderate Interaction) Kidney disease Heart failure Liver problems Disease of the pancreas (pancreatitis) Stones in your gallbladder (gallstones) If you drink alcohol, discuss the safe use of alcohol while using this medication with your healthcare professional. ;

Eliglustat with Weak CYP2D6 Inhibitors (Severe Interaction)

Tamoxifen with Selected Weak CYP2D6 Inhibitors (Moderate Interaction)

Kidney disease

Heart failure

Liver problems

Disease of the pancreas (pancreatitis)

Stones in your gallbladder (gallstones)

If you drink alcohol, discuss the safe use of alcohol while using this medication with your healthcare professional. ;

DA: 82 PA: 1 MOZ Rank: 30

drugbank.com

https://go.drugbank.com/drugs/DB06203

DA: 100 PA: 40 MOZ Rank: 50

wikipedia.org

https://en.wikipedia.org/wiki/Alogliptin

Adverse events include hypoglycemia, pruritis (itching), nasopharyngitis, headache, and upper respiratory tract infection. It may also cause joint pain that can be severe and disabling. Like other DDP-4 inhibitors, alogliptin is weight-neutral. A 2014 letter to the editor claimed alogliptin is not associated with increased risk of cardiovascular events. In April 2016, the U.S. Food and Drug Administration (FDA) added a warning about incr… Formula: C₁₈H₂₁N₅O₂ Pregnancy category: AU: B3

Formula: C₁₈H₂₁N₅O₂

Pregnancy category: AU: B3

DA: 6 PA: 32 MOZ Rank: 63

medicine.com

https://www.medicine.com/drug/alogliptin/hcp

WebFeb 10, 2020 · Source: Wolters Kluwer Health. Last updated January 27, 2020. Includes Alogliptin indications, dosage/administration, pharmacology, mechanism/onset/duration …

DA: 83 PA: 92 MOZ Rank: 6

nih.gov

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3839527/

WebJul 9, 2013 · The recommended dosage of alogliptin is 25 mg once daily with or without food. No dosage adjustment is necessary for patients with mild renal impairment (CrCl 60 …

DA: 98 PA: 92 MOZ Rank: 59